- Home
- CERO vs SNES Comparison
CERO vs SNES Comparison
Compare CERO & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- SNES
- Stock Information
- Founded
- CERO 2017
- SNES 2004
- Country
- CERO United States
- SNES United States
- Employees
- CERO 8
- SNES N/A
- Industry
- CERO
- SNES Agricultural Chemicals
- Sector
- CERO
- SNES Industrials
- Exchange
- CERO Nasdaq
- SNES Nasdaq
- Market Cap
- CERO 3.7M
- SNES 2.9M
- IPO Year
- CERO N/A
- SNES 2016
- Fundamental
- Price
- CERO $0.45
- SNES $2.83
- Analyst Decision
- CERO Buy
- SNES Strong Buy
- Analyst Count
- CERO 2
- SNES 1
- Target Price
- CERO $3.00
- SNES $10.00
- AVG Volume (30 Days)
- CERO 993.4K
- SNES 31.1K
- Earning Date
- CERO 05-15-2025
- SNES 05-08-2025
- Dividend Yield
- CERO N/A
- SNES N/A
- EPS Growth
- CERO N/A
- SNES N/A
- EPS
- CERO N/A
- SNES N/A
- Revenue
- CERO N/A
- SNES $1,927,000.00
- Revenue This Year
- CERO N/A
- SNES $130.53
- Revenue Next Year
- CERO N/A
- SNES $80.00
- P/E Ratio
- CERO N/A
- SNES N/A
- Revenue Growth
- CERO N/A
- SNES 40.15
- 52 Week Low
- CERO $0.40
- SNES $1.30
- 52 Week High
- CERO $102.00
- SNES $7.45
- Technical
- Relative Strength Index (RSI)
- CERO 35.19
- SNES 62.94
- Support Level
- CERO $0.42
- SNES $2.70
- Resistance Level
- CERO $0.50
- SNES $2.90
- Average True Range (ATR)
- CERO 0.05
- SNES 0.15
- MACD
- CERO 0.00
- SNES -0.01
- Stochastic Oscillator
- CERO 24.77
- SNES 79.41
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.